The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma
Sep 17, 2024•almost 2 years ago
Contract Type
partnership
BiotechnologyHealth CareTherapeutics
Description
PharmaJet has entered into a long-term partnership agreement with Scancell Holdings plc to use the PharmaJet Stratis® Intramuscular (IM) Needle-free System for the delivery of its advanced melanoma DNA vaccine. Under the agreement, Scancell will use Stratis for clinical development and commercialization, and PharmaJet will receive milestone payments and royalties on net sales.
Company Information
Company
Scancell
About
The company’s innovative products target post-translational modifications of proteins and lipids. For the vaccines this includes citrullination and homocitrullination of proteins, whereas the monoclonal antibodies target the glycans or sugars on proteins and/or lipids. A driver in the vaccine portfolio is Moditope®, a completely novel class of cancer vaccines that induce potent CD4 cytotoxic T cells that seek out and destroy cancer cells by targeting citrullinated or homocitrullinated proteins.
